TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF
申请人:Mediconns (Shanghai) Biopharmaceutical Co., Ltd
公开号:EP3733670A1
公开(公告)日:2020-11-04
The present invention discloses a tetrahydropyrrole compound, a preparation method therefor, a pharmaceutical composition containing the same, and a use thereof. The tetrahydropyrrole compound of the present invention is represented by general formula (I). The tetrahydropyrrole compound of the present invention has better inhibitory effects on the positive symptoms of schizophrenia, and the potency thereof is equivalent to or slightly stronger than that of the positive drug olanzapine. In addition, the compound of the present invention has dual inhibitory effects on D2 receptors and DAT receptors, and is effective for treating schizophrenia and improving negative symptoms and cognitive functions, while also reducing vertebral side effects and prolactin secretion.
本发明公开了一种四氢吡咯化合物、其制备方法、含有该化合物的药物组合物及其用途。本发明的四氢吡咯化合物由通式(I)表示。本发明的四氢吡咯化合物对精神分裂症阳性症状有较好的抑制作用,其药效与阳性药物奥氮平相当或稍强于奥氮平。此外,本发明化合物对D2受体和DAT受体具有双重抑制作用,能有效治疗精神分裂症,改善阴性症状和认知功能,同时还能减少椎体副作用和催乳素分泌。